Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study).
COVID-19
HIV
comorbidities
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
17
08
2021
accepted:
03
09
2021
pubmed:
24
9
2021
medline:
12
1
2022
entrez:
23
9
2021
Statut:
ppublish
Résumé
The contribution of HIV to COVID-19 outcomes in hospitalized inpatients remains unclear. We conducted a multi-centre, retrospective matched cohort study of SARS-CoV-2 PCR-positive hospital inpatients analysed by HIV status. HIV-negative patients were matched to people living with HIV (PLWH) admitted from 1 February 2020 to 31 May 2020 up to a 3:1 ratio by the following: hospital site, SARS-CoV-2 test date ± 7 days, age ± 5 years, gender, and index of multiple deprivation decile ± 1. The primary objective was clinical improvement (two-point improvement or better on a seven-point ordinal scale) or hospital discharge by day 28, whichever was earlier. A total of 68 PLWH and 181 HIV-negative comparators were included. In unadjusted analyses, PLWH had a reduced hazard of achieving clinical improvement or discharge [adjusted hazard ratio (aHR) = 0.57, 95% confidence interval (CI): 0.39-0.85, p = 0.005], but this association was ameliorated (aHR = 0.70, 95% CI: 0.43-1.17, p = 0.18) after additional adjustment for ethnicity, frailty, baseline hypoxaemia, duration of symptoms prior to baseline, body mass index (BMI) categories and comorbidities. Baseline frailty (aHR = 0.79, 95% CI: 0.65-0.95, p = 0.011), malignancy (aHR = 0.37, 95% CI 0.17, 0.82, p = 0.014) remained associated with poorer outcomes. The PLWH were more likely to be of black, Asian and minority ethnic background (75.0% vs 48.6%, p = 0.0002), higher median clinical frailty score [3 × interquartile range (IQR): 2-5 vs, 2 × IQR: 1-4, p = 0.0069), and to have a non-significantly higher proportion of active malignancy (14.4% vs 9.9%, p = 0.29). Adjusting for confounding comorbidities and demographics in a matched cohort ameliorated differences in outcomes of PLWH hospitalized with COVID-19, highlighting the importance of an appropriate comparison group when assessing outcomes of PLWH hospitalized with COVID-19.
Sections du résumé
BACKGROUND
The contribution of HIV to COVID-19 outcomes in hospitalized inpatients remains unclear. We conducted a multi-centre, retrospective matched cohort study of SARS-CoV-2 PCR-positive hospital inpatients analysed by HIV status.
METHODS
HIV-negative patients were matched to people living with HIV (PLWH) admitted from 1 February 2020 to 31 May 2020 up to a 3:1 ratio by the following: hospital site, SARS-CoV-2 test date ± 7 days, age ± 5 years, gender, and index of multiple deprivation decile ± 1. The primary objective was clinical improvement (two-point improvement or better on a seven-point ordinal scale) or hospital discharge by day 28, whichever was earlier.
RESULTS
A total of 68 PLWH and 181 HIV-negative comparators were included. In unadjusted analyses, PLWH had a reduced hazard of achieving clinical improvement or discharge [adjusted hazard ratio (aHR) = 0.57, 95% confidence interval (CI): 0.39-0.85, p = 0.005], but this association was ameliorated (aHR = 0.70, 95% CI: 0.43-1.17, p = 0.18) after additional adjustment for ethnicity, frailty, baseline hypoxaemia, duration of symptoms prior to baseline, body mass index (BMI) categories and comorbidities. Baseline frailty (aHR = 0.79, 95% CI: 0.65-0.95, p = 0.011), malignancy (aHR = 0.37, 95% CI 0.17, 0.82, p = 0.014) remained associated with poorer outcomes. The PLWH were more likely to be of black, Asian and minority ethnic background (75.0% vs 48.6%, p = 0.0002), higher median clinical frailty score [3 × interquartile range (IQR): 2-5 vs, 2 × IQR: 1-4, p = 0.0069), and to have a non-significantly higher proportion of active malignancy (14.4% vs 9.9%, p = 0.29).
CONCLUSIONS
Adjusting for confounding comorbidities and demographics in a matched cohort ameliorated differences in outcomes of PLWH hospitalized with COVID-19, highlighting the importance of an appropriate comparison group when assessing outcomes of PLWH hospitalized with COVID-19.
Identifiants
pubmed: 34555242
doi: 10.1111/hiv.13174
pmc: PMC8652703
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-133Subventions
Organisme : Medical Research Council
ID : MR/V027549/1
Pays : United Kingdom
Informations de copyright
© 2021 British HIV Association.
Références
J Infect. 2021 Aug;83(2):217-227
pubmed: 34051225
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
J Med Virol. 2021 Mar;93(3):1796-1804
pubmed: 32975842
AIDS. 2020 Nov 1;34(13):F3-F8
pubmed: 32796217
J Acquir Immune Defic Syndr. 2020 Oct 1;85(2):123-126
pubmed: 32675771
Open Forum Infect Dis. 2020 Aug 01;7(8):ofaa327
pubmed: 32864388
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
N Engl J Med. 2020 Dec 17;383(25):2477-2478
pubmed: 33326721
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Infect. 2020 Aug;81(2):e93-e95
pubmed: 32417309
Lancet HIV. 2021 Jan;8(1):e24-e32
pubmed: 33316211
Lancet Public Health. 2020 Aug;5(8):e444-e451
pubmed: 32619408
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
J Clin Epidemiol. 2020 Mar;119:1-6
pubmed: 31715264
HIV Med. 2022 Feb;23(2):121-133
pubmed: 34555242
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
AIDS. 2020 Oct 1;34(12):1775-1780
pubmed: 32773471
AIDS Behav. 2021 Jan;25(1):85-92
pubmed: 32734438
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):6-10
pubmed: 32568770
Clin Med (Lond). 2020 Sep;20(5):e141-e145
pubmed: 32788160
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
HIV Med. 2020 Oct;21(9):567-577
pubmed: 32671970
HIV Med. 2021 May;22(5):372-378
pubmed: 33368966
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
BMJ. 2020 Apr 20;369:m1548
pubmed: 32312785
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Clin Infect Dis. 2014 Dec 15;59(12):1787-97
pubmed: 25182245